CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...